



GE Healthcare

GE Healthcare
Medi-Physics, Inc.
251 Locke Drive
Marlborough, MA 01752

December 4, 2020

Subject: Manufacturing Announcement Regarding Thallous chloride (Tl²⁰¹) Injection

Dear Valued Customer,

We are writing to inform you that GE Healthcare has made the decision to cease the manufacture of Thallium-201 chloride (Tl²⁰¹) Injection effective June 4, 2021.

While we regret that we will no longer be able to offer this product as part of our portfolio, alternative GE Healthcare molecular imaging tracers are available and may, in some circumstances, be appropriate. Should you wish to continue use of Thallium-201 chloride, alternative commercial suppliers are available and can be found via the US Food and Drug Administration (FDA) website.

The last manufacturing date for Thallium will be Friday, June 4, 2021. The last calibration date will be Thursday, June 10 and the product expiration date is Tuesday, June 15, 2021. Ordering deadlines remain unchanged.

GE Healthcare remains committed to molecular imaging and will continue to provide our customers with a broad portfolio of PET and SPECT tracers while also continuing to invest in new branded agents.

We hope that this announcement provides adequate time to establish an alternative product option. Should you have any questions or concerns, please do not hesitate to reach out to your local GE Region Clinical Leader for further assistance. For Clinical or Scientific inquiries, please contact our GE Medical Affairs Team at 800 654 0118 (option 2, then option 3).

Thank you for your trust in us and continued business, and we look forward to serving you in the future.

Sincerely,

A handwritten signature in black ink, appearing to read 'M. Wysocki'.

Michael Wysocki
General Manager, Molecular Imaging
GE Healthcare